Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors

Targeting tumour microenvironment by tyrosine kinase inhibitor

(2018) Hor-Yue Tan et al.   Molecular Cancer

A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors

(2016) Klaus Mross et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma

(2015) Graham P. Collins et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

(2015) Guillermo Garcia-Manero et al.   INVESTIGATIONAL NEW DRUGS

Targeting cancer with kinase inhibitors

(2015) Stefan Gross et al.   JOURNAL OF CLINICAL INVESTIGATION

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

(2015) William D. Tap et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypertension Due to Antiangiogenic Cancer Therapy With Vascular Endothelial Growth Factor Inhibitors: Understanding and Managing a New Syndrome

(2014) Heather Yvonne Small et al.   CANADIAN JOURNAL OF CARDIOLOGY

Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab

(2014) Jim Zhong et al.   CANCER

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors

(2014) Gerald S. Falchook et al.   INVESTIGATIONAL NEW DRUGS

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study

(2014) Gerald Falchook et al.   INVESTIGATIONAL NEW DRUGS

A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors

(2014) Christian Dittrich et al.   INVESTIGATIONAL NEW DRUGS

Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML

(2013) Hagop M. Kantarjian et al.   Clinical Lymphoma Myeloma & Leukemia

Influence of tumour micro-environment heterogeneity on therapeutic response

(2013) Melissa R. Junttila et al.   NATURE

Sorafenib in Advanced Hepatocellular Carcinoma

(2012) Bassam Estfan et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

(2010) J. R. Diamond et al.   CLINICAL CANCER RESEARCH

Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker

(2010) Emily S. Robinson et al.   SEMINARS IN NEPHROLOGY